Amarin | AMRN - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.27B 1000K 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
AstraZeneca USD 12.22B 4.04B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
DBV Technologies USD 47.9M 2.2M 2026-03
GlaxoSmithKline GBP 5.8B 468M 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06